Ardea Biosciences Inc

Ardea Biosciences — Corporate Update (January 2010)

40 slides from Ardea Biosciences's corporate update, Jan 11, 2010

  1. Slide 1: Company Update January 11, 2010

    Company Update January 11, 2010

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results

  3. Slide 3: Status of Development Programs

    Status of Development Programs RDEA427 RDEA806 900 Series Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV MEKI for cancer 3 Gout RDEA594 RDEA684 MEKI + sorafenib for cancer RDEA119 Gout Partnered with Bayer RDEA119 3rd Gen NNRTIs

  4. Slide 4: Gout/Hyperuricemia

    Gout/Hyperuricemia Ardea) Biosciences

  5. Slide 5: Refractory Disease Has Not Disappeared

    Refractory Disease Has Not Disappeared 5

  6. Slide 6: Hyperuricemia/Gout - Unmet Medical Need

    Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease Attacks of severe pain/Inflammation Disfiguring nodules (tophi) Kidney damage (nephropathy) Increasing incidence and severity in U.S. (> 5,000,000 potential

  7. Slide 7: Uric Acid Production and Elimination

    Hare, J. M. et al. Circulation 2003;107:1951-1953 Uric Acid Production and Elimination Allopurinol Febuxostat RDEA594 Probenecid Losartan (Cozaar(r)) Benzbromarone* 7 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. Pegloticase URAT1

  8. Slide 8: URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid

    >99% Reabsorption Excretion ~100% of uric acid is initially filtered through glomerular filtration URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid URAT1 Enomoto; Urat1 identification in Nature May2002 D Levinson & L Sorensen; Renal Handling of Uric Acid Proximal Tubule Benzbromarone RDE

  9. Slide 9: Selective URAT1 Transporter Inhibition: An Important Contribution to the Treatment of Hyperuricemia/Gout

    9 Selective URAT1 Transporter Inhibition: An Important Contribution to the Treatment of Hyperuricemia/Gout Inhibition of the URAT1 transporter is a well-validated target for gout Benzbromarone has over 10 million patient-years of treatment experience, with very few side effects, except liver toxicit

  10. Slide 10: Combining RDEA594 with XO Inhibitor Should Accelerate Clearance of Urate from Body Pools

    Diet & Metabolism 600-800 mg/day Joint Tophus 10 mg/dL 6 mg/dL serum level Xanthine Oxidase Inhibitor URAT1 Inhibitor <5 mg/dL Combining RDEA594 with XO Inhibitor Should Accelerate Clearance of Urate from Body Pools urine urine 300 mg/day 200 mg/day 600 mg/day 10

  11. Slide 11: Uric Acid-Lowering Was Noticed With RDEA806

    Uric Acid-Lowering Was Noticed With RDEA806 Up to 45% reductions in serum urate (sUA) were observed in healthy volunteers in the 10-day multiple ascending dose study of RDEA806 Uric acid reductions were also observed in all HIV patients in the Phase 2a monotherapy study with RDEA806 A 28-day proof-o

  12. Slide 12: RDEA594 Preclinical and Phase 1 Summary

    RDEA594 Preclinical and Phase 1 Summary RDEA594 is a selective inhibitor of the URAT1 renal transporter (EC50 = 5-10 ^M) without antiviral activity No interactions with antivirals or other drugs secreted by OAT1 and OAT3 transporters observed in humans or animals Limited metabolism by CYP450 Inhibit

  13. Slide 13: RDEA594 Phase 2a Pilot Pharmacodynamic and Safety Study in Gout Patients

    Arm 1:RDEA594 200 mg QD Screenin g Period Colchicine Treatment Randomize if no gout flare during 2 weeks of colchicine Off drug Off drug Arm 2: Placebo 400 mg QD Off drug Arm 3: Allopurinol 300 mg 5 pts 5 pts 11 pts 7-21 days 1 week 2 weeks total with dose escalation of RDEA594 after Week 1 1 week P

  14. Slide 14: Phase 2a Cohort Baseline Demographics

    Phase 2a Cohort 1 Baseline Demographics Parameter Placebo RDEA594 Allopurinol Age Mean (SD) Mean (SD) 50.2 (9.5) 54.3 (13.7) 43.4 (5.9) (years) Median Median 51 56 43 Min, Max Min, Max 40, 65 27, 72 35, 56 BMI Mean (SD) Mean (SD) 33.4 (4.2) 27.8 (3.1) 31.4 (6.9) (kg/m2) Median Median 32.2 27.7 29.2

  15. Slide 15: Both Active Arms Produced Significant Reductions in sUA

    Randomized Drug Washout Period All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers Response defined as < 6.0 mg/dL Placebo % (n/N) RDEA594 % (n/N) Allopurinol %

  16. Slide 16: 83% Response in Renally Impaired Patients Observed with RDEA594

    83% Response in Renally Impaired Patients Observed with RDEA594 All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with

  17. Slide 17: 54% Reduction in SUA and 100% Response with RDEA594 Combined with Allopurinol

    ** ** * ** ** * *P<0.10; **P<0.05 for Allo vs combo LOCF used for allopurinol due to incomplete data 54% Reduction in SUA and 100% Response with RDEA594 Combined with Allopurinol RDEA594 400 mg + Allopurinol produced a reduction of sUA from a mean of 10.2 mg/dL to 4.7 mg/dL, with 100% of patients <

  18. Slide 18: RDEA594 and Allopurinol Combination Product Under Development

    RDEA594 and Allopurinol Combination Product Under Development Allopurinol 300 mg (Zyloprim) RDEA594 400 mg RDEA594 400 mg and Allopurinol 300 mg Reference for Size, Tylenol(r) GelCap 18

  19. Slide 19: Phase 2a - Urinary Excretion of Uric Acid

    Phase 2a - Urinary Excretion of Uric Acid Gout patients RDEA594 normalizes uric acid excretion in gout patients with inadequate excretion Allopurinol reduces uric acid excretion even further in patients with already low excretion The combination of these two agents reduces production, but also incre

  20. Slide 20: Phase 2a Adverse Events by Treatment Group

    Treatment Group Mild Moderate Severe Serious Adverse Event Treatment Group (grade 1) (grade 2) (grade 3) Serious Adverse Event Treatment Group N Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Nu

  21. Slide 21: Undissociated Urinary Uric Acid is the Most Important Risk Factor for Nephrolithiasis

    Undissociated Urinary Uric Acid (UUua) is the Most Important Risk Factor for Nephrolithiasis* 21 Patients on uricosurics with UUua<20 mg/dL had same rate of lithiasis as patients on allopurinol * 2009 ACR Philadelphia, Presentation 1499 Risk Factors for Renal Lithiasis During the Treatment with Uric

  22. Slide 22: RDEA594-105: Febuxostat Drug-Drug Interaction and PD Study

    RDEA594-105: Phase 1 Febuxostat Drug-Drug Interaction and PD Study - Completed Population: 36 normal healthy volunteers with sUA ^ 6 mg/dL; 18 per dose panel Males and postmenopausal or sterile women 18 - 65 years of age, inclusive 2 panels with escalating doses of RDEA594 or placebo - 200 mg and 40

  23. Slide 23: No Pharmacokinetic Interactions Observed Between RDEA594 and Febuxostat

    No Pharmacokinetic Interactions Observed Between RDEA594 and Febuxostat at Steady-State 23 Febuxostat RDEA594 Pharmacokinetic results for the 400 mg dose group are pending

  24. Slide 24: Combination of RDEA594 and Febuxostat Produced 70% - 80% Reductions in sUA

    Combination of RDEA594 and Febuxostat Produced 70% - 80% Reductions in sUA Febuxostat 160mg in healthy subjects* *Khosravan, et al. Clin Pharmacokinet 2006; 45 (8): 821-841 24 The combination arms are significantly different from febuxostat alone at all points from Days 9-15: p < 0.001 60 - 70% mean

  25. Slide 25: Pegloticase FDA Committee Slides

    25 Pegloticase FDA Committee Slides Approximately 50% mean reduction with q4 week regimen (9.8 to 5.2 mg/dL) Approximately 65% mean reduction with q2 week regimen (9.8 to 3.5 mg/dL) 25

  26. Slide 26: RDEA594 Results Superimposed on Pegloticase Data

    26 RDEA594 Results Superimposed on Pegloticase Data RDEA594 + Allopurinol from Study 201 (projected out in time) RDEA594 + Febuxostat (projected data from NHV study) 26

  27. Slide 27: Projected sUA lowering with RDEA594 + febuxostat compared to pegloticase

    27 27 The sUA lowering with RDEA594 + febuxostat is projected to be similar to what was achieved with the q2 week regimen of pegloticase; however, to be conservative we are using a 20% response rate from the q4 week regimen for powering our proposed study

  28. Slide 28: Overall Summary of Safety for RDEA594 Through Phase 2a

    Overall Summary of Safety for RDEA594 Through Phase 2a Patients exposed to RDEA594 (either administration of RDEA594 or RDEA806): Healthy subjects and HIV pts ~360 for up to 14 days Gout patients ~ 40 for up to 28 days Control subjects ~ 88 28 Arm Discontinuations Due to AEs N (%) Serious Adverse Ev

  29. Slide 29: RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities

    RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities Phase 2b monotherapy dose-response, safety and efficacy study (n=140) Supports use in patients who are intolerant to allopurinol, inadequate responders to allopurinol, and first-line treatment Phase 2b allopurinol add-on study in

  30. Slide 30: RDEA594 Phase 2b Monotherapy Dose-Response, Safety and Efficacy Study

    RDEA594 Phase 2b Monotherapy Dose- Response, Safety and Efficacy Study - Enrolling 21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) total of 140 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose will

  31. Slide 31: RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study

    RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study - Enrolling Dose Escalation Based on sUA Lowering with 200 mg RDEA594: 18 patients initially, including 12 patients randomized to RDEA594 and 6 patients randomized to placebo 31 RDEA594 100 mg or placebo plus allopurinol 300 m

  32. Slide 32: RDEA594-204: Renal Impairment in Patients with Gout and Hyperuricemia

    RDEA594-204: Renal Impairment in Patients with Gout and Hyperuricemia - Enrolling Cohort 1A: (6 subjects) 200 mg RDEA594 Subjects must have moderate renal impairment defined as creatinine clearance from (CrCL) ^ 30 mL/min to < 60 mL/min. Subjects will receive RDEA594 once daily for 5 days. Cohorts 1

  33. Slide 33: There is a large unmet need for new treatments for gout

    33 There is a large unmet need for new treatments for gout RDEA594, a selective URAT1 transport inhibitor, corrects the physiologic cause of 90% of hyperuricemia: uric acid under-excretion Clinical proof-of-concept has been achieved for both monotherapy, and in combination with xanthine oxidase inhi

  34. Slide 34: RDEA684 - Development Candidate Selection

    RDEA684 - Development Candidate Selection RDEA684 was selected for further development based on the following criteria: Potency improved by up to 200-fold compared to RDEA594 Clean in initial toxicology screen, including 7-day rat, genetox, mitochondrial tox, and ligand screening (MDS) Comparable mi

  35. Slide 35: Cancer MEK program licensed to Bayer Healthcare

    Cancer 35 MEK program licensed to Bayer Healthcare on April 28, 2009 $35 million upfront license fee Payments could total $407 million, excluding royalties Low double-digit royalties on worldwide sales Ardea responsible for completing two dose-finding studies (expected completion 1H10)

  36. Slide 36: The Age of Targeted Cancer Treatments

    The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) XL518 (Ph 1) RDEA119 (Ph 1/2) RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 36

  37. Slide 37: RDEA119 is Potent, Highly Specific MEK Inhibitor

    RDEA119 is Potent, Highly Specific MEK Inhibitor MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK

  38. Slide 38: Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines

    Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines 38

  39. Slide 39: Financial Position Summary

    Financial Position Summary Statement of Operations (In thousands, except per share data) Nine Months Ended Sept. 30, 2009 Revenue Operating expenses Other expense $ 14,681 38,527 (691) NET LOSS $(24,537) NET LOSS PER SHARE $(1.36) 18.5 million common shares outstanding Expect 2009 year-end cash bala

  40. Slide 40: Near-Term Anticipated Milestones

    Near-Term Anticipated Milestones Drug Candidate Event Date Date Gout Gout Gout Gout RDEA594 Phase 2b Start in 7/09 Phase 2b Start in 7/09 ? RDEA594 Phase 2a - Cohort 2 Allopurinol Combo Results Phase 2a - Cohort 2 Allopurinol Combo Results ? RDEA594 Febuxostat Combination Study Results Febuxostat Co

Ardea Biosciences — Corporate Update (January 2010) on 6ix